HAEMONETICS CORPORATION
Ownership & governance
Executives 5Directors 9Avg age 66Avg tenure 7.4y
CS
Christopher Simon
Chief Executive Officer
Age 62Since 2016-05-15Profile →
+13
Executives5
CS
Christopher Simon→
Chief Executive Officer
Age 62Since 2016-05-15
JD
James D'Arecca→
Director of Finance/CFO
Age 55Since 2022-04-10
FC
Frank Chanx→
Chief Operating Officer
Age 56Since 2025-03-31
JH
Jan Hartmann→
Chief Tech/Sci/R&D Officer
—Since 2023-03-31
OG
Olga Guyette→
Investor Relations Contact
—Since 2019-10-31
Board of directors9
MK
Mark Kroll→
Director/Board Member
Age 73Since 2005-12-31
CD
Charles Dockendorff→
Director/Board Member
Age 71Since 2014-07-22
CS
Christopher Simon→
Director/Board Member
Age 62Since 2016-05-15
RA
Robert Abernathy→
Director/Board Member
Age 71Since 2017-10-17
EZ
Ellen Zane→
Chairman
Age 74Since 2021-08-05
CP
Claire Pomeroy→
Director/Board Member
Age 71Since 2019-04-23
MC
Michael Coyle→
Director/Board Member
Age 64Since 2020-04-15
LJ
Lloyd Johnson→
Director/Board Member
Age 71Since 2021-08-05
Shareholders5
| Name | Stake | Shares |
|---|---|---|
| BlackRock Advisors LLC | 11.64 % | 5,291,983 |
| LB Hercules Holdings LLC | 7.835 % | 3,560,918 |
| AQR Capital Management LLC | 7.386 % | 3,356,543 |
| Vanguard Portfolio Management LLC | 5.632 % | 2,559,316 |
| Vanguard Capital Management LLC | 4.6 % | 2,090,389 |
Catalog · 2026-07-09
SEC officers15
| Name | Role | Since | Shares |
|---|---|---|---|
| Christopher Simon | Chief Executive Officer | — | - |
| Ellen Zane | Chairman | — | - |
| Frank Chanx | Chief Operating Officer | — | - |
| James D'Arecca | Director of Finance/CFO | — | - |
| Jan Hartmann | Chief Tech/Sci/R&D Officer | — | - |
| Charles Dockendorff | Director/Board Member | — | - |
| Christopher Simon | Director/Board Member | — | - |
| Claire Pomeroy | Director/Board Member | — | - |
SEC · as of 2026-07-28
Group companies
| Name | Category |
|---|---|
| Haemonetics Manufacturing, Inc. | Medical Specialties |
| Haemonetics Manufacturing, Inc. | Medical Specialties |
| Haemonetics SA | Packaged Software |
| Haemonetics SA | Packaged Software |
Institutional (13F)
Loading Form 13F holders…
Fund membership
Loading fund baskets…
Street consensus
Consensus buyMean target 122.2Range 86–140Analysts 10
86Mean 122.2140
- Strong buy 4
- Buy 5
- Hold 2
Broker actions40 of 186
| Firm | Action | To | Target | Date |
|---|---|---|---|---|
| Barrington Research | Maintained | Outperform | 140 | 2026-10-09 |
| Mizuho | Maintained | Outperform | 140 | 2026-10-09 |
| BTIG | Maintained | Buy | 130 | 2026-10-08 |
| Citigroup | Upgrade | Buy | 123 | 2026-09-17 |
| Raymond James | Maintained | Outperform | 125 | 2026-09-03 |
| Baird | Maintained | Outperform | 119 | 2026-08-21 |
| Barrington Research | Maintained | Outperform | 118 | 2026-08-19 |
| BTIG | Maintained | Buy | 110 | 2026-08-18 |
| Citigroup | Maintained | Neutral | 92 | 2026-08-07 |
| JP Morgan | Maintained | Neutral | 86 | 2026-08-07 |
| BTIG | Maintained | Buy | 96 | 2026-08-06 |
| Mizuho | Maintained | Outperform | 90 | 2026-07-15 |
Firm rows and rating mix from Yahoo Finance; mean target is Yahoo’s aggregate until OpenFilings derives consensus from broker rows.